Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$4.58 ▼ -0.56
(-10.89%)
MKT CAP: $70.3M • VOL: 1.36M
52W L $3 52W H $37
ROARABLE / RQD
E • 32/100
PIOTROSKI
2 / 9
GRML // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.1M | -$5.5M | -$631.3K |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$10.6M | -$6.2M | -$707.5K |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.9M | -$2.9M | -$446.9K |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$5.9M | -$2.9M | -$446.9K |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $7.2M | $63.7K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $9.5M | $1.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR GRML.